Cosmo Pharmaceuticals Methylene Blue MMX Regulatory Update:
Type A Meeting outcome – Next steps
Cosmo Pharmaceuticals N.V. today provided a regulatory update after receipt of the official meeting minutes from the requested July 2018 Type A Meeting with the FDA Medical Imaging Division to discuss the path forward for MB MMX, a product for visualization of lesions in patients undergoing colonoscopy to improve overall detection of adenomas and carcinomas.